Evaxion Biotech A/S American Depositary Share
EVAX Real Time Price USDRecent trades of EVAX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EVAX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Jun. 11, 2024
-
Patent Title: Peptides derived from Jan. 02, 2024
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Nov. 07, 2023
-
Patent Title: Vaccines targeting Aug. 08, 2023
-
Patent Title: Chimeric proteins for inducing immunity towards infection with Aug. 16, 2022
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Jul. 06, 2021
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Mar. 16, 2021
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Dec. 01, 2020
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Jun. 09, 2020
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Oct. 08, 2019
-
Patent Title: Proteins and nucleic acids useful in vaccines targeting Jul. 31, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of EVAX in WallStreetBets Daily Discussion
Recent insights relating to EVAX
Recent picks made for EVAX stock on CNBC
ETFs with the largest estimated holdings in EVAX
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view EVAX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.